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The key structural and signaling roles
of collagen in the extracellular matrix
(ECM) make it an attractive biomaterial
for tissue engineering, but there are lim-
itations in the standardization and purity
of natural collagen sources currently avail-
able for such applications (Ruggiero and
Koch, 2008; Werkmeister and Ramshaw,
2012). Significant effort has been made
to produce human collagen in recombi-
nant systems, such as yeast, insect cells and
plants (Ruggiero et al., 2000; Myllyharju,
2009). However, the requirement for post-
translational proline hydroxylation has
proven to be a significant obstacle in
achieving large scale production. Recent
findings of collagen-like proteins in bacte-
ria suggest these may represent alternative
biosynthetic collagen materials which may
complement current sources.
Over the past 10 years, collagen-like
proteins have been identified from numer-
ous bacterial genomes database based
on the signature (Gly-Xaa-Yaa)n repeat-
ing amino acid sequence characteristic
of the collagen triple-helix (Rasmussen
et al., 2003; Yu et al., 2014). Some of
these collagen-like molecules may func-
tion as virulence factors by bacteria to
evade the immune system of higher ani-
mals or to interact with surface recep-
tors or with other ECM molecules nec-
essary to promote host cell invasion
(Humtsoe et al., 2005). More than 100
putative collagen-like proteins have been
identified in bacterial genomes, of which
eight have been recombinantly expressed
in Escherichia coli (see Yu et al., 2014
for review). All eight expressed bacterial
collagens were shown to form stable
triple-helices with Tm∼35–39◦C. E. coli
and most bacteria lack prolyl hydroxy-
lase, so this high stability is attained in
the absence of hydroxyproline (Hyp), a
post-translationally modified amino acid
known to be critical to the thermal stabil-
ity of mammalian collagens. Initial interest
in bacterial collagen-like proteins focused
on their roles in pathogenesis. However,
recent work has focused on one specific
bacterial collagen protein, designated Scl2,
to demonstrate the utility of recombinant
bacterial collagen as a tool for defining
collagen sequence/structure/function rela-
tionships and for establishing a class of
novel collagen-based biomaterials.
The gram positive bacterium
Streptococcus pyogenes contains two
collagen-like proteins, Scl1 and Scl2, which
have been well characterized in terms
of structure and functional properties
(Lukomski et al., 2001; Xu et al., 2002;
Mohs et al., 2007; Caswell et al., 2008).
The Scl2 protein includes an N-terminal
globular trimerization domain adjacent
to a (Gly-Xaa-Yaa)79 core collagen-like
domain. It has been possible to generate
constructs in a recombinant E. coli system
with various sequence modifications of
Scl2 and to establish large scale production
methods. Based on recent progress, we
suggest that the Scl2 recombinant bacterial
collagen system has advantages compared
to recombinant human collagen strategies
for large scale production and biomedical
applications, and may serve as a proto-
type for engineering novel collagen-based
biomaterials.
STABLE TRIPLE HELICAL PROTEIN
WITHOUT HYDROXYPROLINE
The recombinant Scl2 protein and its
modified variants are able to form a
triple helix with stability similar to that
of mammalian collagens (Tm∼37◦C) even
though there is no Pro hydroxylation.
In animal collagens, Pro residues in
the Y positions of the repeating Gly-X-
Y sequence are hydroxylated to Hyp, and
this hydroxylation is required to stabi-
lize the triple-helix: Tm of hydroxylated
collagen = 37◦C, while Tm of unhy-
droxylated collagen = 26◦C (Berg and
Prockop, 1973; Jimenez et al., 1973). The
bacterial collagen appears to compensate
for the absence of Hyp with electro-
static interactions (Mohs et al., 2007). In
yeast, plants, and other expression sys-
tems for human collagens, the genes for
the alpha and beta subunits of human
prolyl hydroxylase (P4H) must be intro-
duced to form stable collagen molecules
(Ruggiero et al., 2000; Myllyharju, 2009;
Xu et al., 2011; Shoseyov et al., 2014).
However, P4H activity and hydroxylation
levels are highly dependent on expression
conditions, such as the gene copy ratio of
collagen to hydroxylase, concentration of
cofactors, induction time, and sequence
(Chan et al., 2012), so generating opti-
mal hydroxylation to model native human
collagen has been challenging in systems
with inserted P4H genes and even in
mammalian cell expression systems. The
bacterial collagen-like proteins are highly
compatible with expression in E. coli, and
the lack of requirement for any post-
translational modifications presents the
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potential for producing large quantities of
recombinant stable triple-helical proteins
for biomaterials applications.
MIX AND MATCH FUNCTIONAL
MODULAR UNITS
In addition to production advantages, the
ability to express the collagen-like pro-
tein in E. coli allows easy manipulation
of the sequence to enhance biomaterial
properties. Insertion of known human col-
lagen binding sites within Scl2 presents
the possibility of designing collagen-like
materials with defined biological proper-
ties. The native human collagen sequence
contains more than 40 binding sites which
interact with other biologically functional
molecules, including cell receptors, other
ECM proteins and collagenases (MMPs)
(Kadler, 1994). Examination of the Scl2
recombinant protein suggests that this
particular bacterial collagen-like protein
lacks any known biologically active sites,
making it a convenient blank slate for
the introduction of human collagen lig-
and binding sites (Caswell et al., 2008;
Cosgriff-Hernandez et al., 2010). Various
human-derived collagen short amino acid
sequences (2–6 triplets) with identified
bioactive sites have been inserted into
the Scl2 collagen-like domain, including
sites for binding integrin α2β1 (Seo et al.,
2010), fibronectin (An et al., 2014), hep-
arin (Peng et al., 2013), and MMPs (Yu
et al., 2012). The inserted sequences have
conferred the expected biological activi-
ties on the Scl2 protein based on in vitro
binding, cleavage, and cell culture assays.
The Scl2 sequence will apparently fold
the short human collagen insert into a
triple helix, while the correctly folded
human collagen sequence imparts the
corresponding biological function to the
chimeric protein. The introduction of
the integrin and fibronectin binding sites
promoted the growth of different types
of mammalian cells in vitro, while Scl2
molecules with MMP cleavage sites show
enzyme cleavage at the native position.
More collagen bioactive sites are being
identified each year primarily through
synthetic collagen mimetic Toolkit pep-
tides (Farndale et al., 2008), providing an
increasing pool of candidates for a recom-
binant chimeric bacteria-human library
with human collagen functions. Such a
recombinant library is particularly useful
for applying a synthetic biology “plug and
play” concept to future biomaterial designs
(Figure 1). Only those collagen biological
functions that are required for a particu-
lar application will be selected and incor-
porated into a final product, leading to
precise tuning for each application.
MOLECULAR AND HIGHER ORDER
STRUCTURE
With recombinant DNA technologies, it
has been possible to manipulate the Scl2
protein, studying individual fragments
of the triple-helix (Yu et al., 2011) or
duplicating the entire triple-helix portion
(Yoshizumi et al., 2009), while maintain-
ing secondary structure and stability. Scl2
is a homotrimer, serving as a model for
homotrimeric collagens such as type II
collagen in cartilage. To better mimic het-
erotrimeric collagens such as the domi-
nant type I collagen in bone and tendon
or type IV collagen in basement mem-
brane, it may be possible to replace the
natural trimerization V domain with a
heterotrimic coiled coil (Nautiyal et al.,
1995) or an electrostatic interaction chain
selection mechanism (Jalan et al., 2013).
While facile manipulation of the Scl2
protein can optimize molecular and bio-
logical properties, successful biomaterial
applications will require optimization
of material properties as well. The most
abundant animal collagens self-associate
into characteristic periodic cross-linked
fibrils, which provide the mechanical
properties for tissues and biomaterials.
Thus far, Scl2 exhibits limited ability to
form fibrillar structures (Yoshizumi et al.,
2009). The Scl2 triple-helix is only about
1/5 of the length of the human fibrillar
collagen triple-helix, and it is possible
that increasing its length will promote
self-association. The E. coli system usu-
ally has an upper threshold for the size of
the recombinant protein it can produce,
but it may be possible to transfer the Scl2
expression system into yeast or insect cells
to further increase its chain length. Crystal
structures on small collagen model pep-
tides and studies on recombinant tobacco
type I collagen suggest Hyp may be essen-
tial for collagen fibril formation (Kramer
et al., 2000; Perret et al., 2001). Thus, it
may be necessary to introduce P4H genes
into the bacterial system in order to induce
fibril formation, even though the Hyp is
not necessary to form the stable triple-
helix. Alternative approaches to attaining
an optimal self-supporting material from
Scl2 include chemical modifications such
as glutaraldehyde vapor or 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide
or crosslinking by poly(ethylene glycol)
diacrylate to form interchain networks
(Cosgriff-Hernandez et al., 2010; Peng
et al., 2010). Chemical modifications
are simple and effective, but the level of
crosslinking maybe difficult to control,
especially in large 3D scaffolds, and a high
degree of cross-linking may limit acces-
sibility to biologically active sites within
the collagen material. Another strategy
recently reported involved non-covalent
binding of Scl2 constructs with fibronectin
and integrin interaction sites to solid silk
protein material, generating porous silk
scaffolds with improved support of cell
growth (An et al., 2013) (Figure 1).
PURIFICATION, SCALABILITY, AND
PROJECTED COST
Animal extracted collagens are produced
in large quantity and are generally inex-
pensive. However, difficulties in devel-
oping standardized preparations of these
collagens and in producing minor types
of collagens that are free of collagen I
and biological contaminants are major
limitations. Potential infectious and aller-
gic risks of animal collagen products are
also a concern. The recombinant bac-
terial collagens have attached tags, such
as His-tag and Strep II tags to simplify
standardized chromatographic purifica-
tion. A high-throughput batch purifica-
tion methodology for Scl2 has also been
developed (Peng et al., 2014). Native triple
helical sequences are resistant to digestion
by non-specific enzymes such as trypsin
and chymotrypsin, and trypsin treatment
of acidified cell lysate resulted in purified
triple helical bacterial collagen. Enzymatic
digestion during the purification process
ensures the final product will be free of
non-triple helical contaminants, which is
important for quality control for indus-
trial production. Recombinant expression
of proteins in E. coli is a mature indus-
trial process with excellent scalability. This
has already been demonstrated for Scl2
production (Peng et al., 2012) with an
average yield of 0.2–0.3 g/L of purified col-
lagen protein in traditional shaking flask
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FIGURE 1 | Schematic diagram of recombinant bacterial collagen production method and material fabrication strategies. hCol, human collagen; bCol,
recombinant bacterial collagen Scl2.
culture and up to 9.5 g/L in high density
fed-batch culture. With the ease of gen-
erating different Scl2 constructs through
molecular cloning, the overall resource
cost for producing this highly tunable
bacterial collagen material will likely be
lower than recombinant collagen obtained
from mammalian cell or even transgenic
systems.
TOWARD IN VIVO APPLICATIONS
Translational science remains a less
explored area for recombinant collagens.
Recombinant human collagens obtained
from systems with high scalability, such
as Pichia and Nicotiana, have been for-
mulated into hydrogels and explored for
their potential as artificial cornea (Merrett
et al., 2008) and wound dressings (Shilo
et al., 2013), respectively. In terms of bac-
terial collagen, Scl2 has been shown to
be non-immunogenic, non-cytotoxic and
non-thrombogenic (Peng et al., 2010).
Recently, poly(ethylene glycol) crosslinked
bioactive Scl2 hydrogels have been rein-
forced with an electrospun polyurethane
mesh to achieve suitable biomechanical
property for vascular grafts (Browning
et al., 2012). The rate of cell migra-
tion is tunable through altering protein
concentration in the material. Further
investigation, especially the degradation
and turnover time of Scl2 material in vivo
is needed to evaluate its suitability as
medical implants.
CRITICAL PROPERTIES FOR A
SUCCESSFUL COLLAGEN PRODUCTION
STRATEGY
Figure 1 illustrates the current production
method and material fabrication strate-
gies for recombinant bacterial collagen
Scl2. Large amounts of bioactive collagen
molecules can be produced with simple
gene manipulation, large scale produc-
tion and high throughput purification.
Functional collagen proteins could then be
cross-linked into hydrogels or used as coat-
ing on other solid materials. Conditions
and sequence manipulations which would
trigger Scl2 self-assembly into large fibers
are currently under investigation. Such
fabricated materials could lead to the ulti-
mate goal of designing and developing
artificial extracellular matrices, an objec-
tive important for tissue engineering as
well as biomedical fields. With its high
tunability and scalability accompanied by
low complexity and cost, we believe the
Scl2 recombinant bacterial collagen sys-
tem has clear advantages which could not
only circumvent the difficulties seen for
recombinant human collagens, but also
open up a brand new pathway for collagen
production.
LONG TERM PROSPECTS
Extracted bovine collagen is likely
to remain a staple for biomaterial
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construction due to its low cost and use-
ful material properties, but challenges in
standardization and concerns for biobur-
dens, as well as a desire to modify collagen
sequence and function, will lead to contin-
ued interest in research and applications
with recombinant collagens. As described
here for the specific Scl2 protein from
S pyogenes, bacterial collagens repre-
sent a biosynthetic ground up approach,
where a triple-helical non-animal collagen
molecule with no specific bioactivity can
be designed to include desired interac-
tions and regulated degradation. Although
research has focused on Scl2, the approach
could be extended to other collagen-like
proteins from bacteria and viruses, which
may bring new properties and variations
useful for biomaterials. Fundamental stud-
ies on Scl2 and other bacterial collagens
will continue to elucidate basic features
of collagen, with a focus on chemistry,
sequence, biological activity, and self-
assembly. The success of the bacterial
collagen approach toward biomaterial
applications will depend on developing
the capacity to generate biomaterials with
desirable biomechanical properties useful
for in vivo applications.
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